About
Periodic safety update report single assessments (PSUSAs) are single assessments of related periodic safety update reports (PSURs) for active substances contained in medicines authorised in the European Union (EU). A PSUR is a pharmacovigilance report submitted regularly by a marketing-authorisation holder at defined time points following a medicine's authorisation.
Key facts
- Active substance(s) in scope of the PSUSA procedure
- Levothyroxine
- Procedure number
- PSUSA/00001860/202201
- Regulatory outcome
- Variation
Documents
Levothyroxine : List of nationally authorised medicinal products - PSUSA/00001860/202201
English (EN) (463.85 KB - PDF)
Levothyroxine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001860/202201
English (EN) (142.3 KB - PDF)
български (BG) (203.53 KB - PDF)
español (ES) (130.45 KB - PDF)
čeština (CS) (184.65 KB - PDF)
dansk (DA) (135.7 KB - PDF)
Deutsch (DE) (143.88 KB - PDF)
eesti keel (ET) (133.38 KB - PDF)
ελληνικά (EL) (177.8 KB - PDF)
français (FR) (139.79 KB - PDF)
hrvatski (HR) (173.79 KB - PDF)
íslenska (IS) (139.56 KB - PDF)
italiano (IT) (134.87 KB - PDF)
latviešu valoda (LV) (189.55 KB - PDF)
lietuvių kalba (LT) (209.08 KB - PDF)
magyar (HU) (157.93 KB - PDF)
Malti (MT) (183.19 KB - PDF)
Nederlands (NL) (136.65 KB - PDF)
norsk (NO) (135.24 KB - PDF)
polski (PL) (173.81 KB - PDF)
português (PT) (137.81 KB - PDF)
română (RO) (174.32 KB - PDF)
slovenčina (SK) (181.83 KB - PDF)
slovenščina (SL) (176.95 KB - PDF)
Suomi (FI) (125.96 KB - PDF)
svenska (SV) (135.12 KB - PDF)